Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma
作者： Diego Carlos dos Reis , Cristina Maria de Souza , Liliane Cunha Campos , Ana Cândida Araújo e Silva , Miriam Teresa Paz Lopes
DOI: 10.1590/S1676-24442014000100009
关键词: Whole blood 、 Tumor growth 、 Hematology 、 Internal medicine 、 Left flank 、 Leukocytosis 、 Inoculation 、 Medicine 、 Pathology 、 Thalidomide 、 Mammary carcinoma
摘要: The aim of this study was to evaluate the therapy effect thalidomide in 4T1 murine mammary carcinoma. cell suspension injected into posterior left flank all animals obtain solid tumors. Five days after inoculation, treatment group orally administered 150 mg/kg for seven days. Tumors were measured every 48 hours until end treatment. Whole blood collected hematology analysis. Our results suggest that increase number circulating leukocytes carcinoma, and response is accompanied by a decrease tumor growth.
sci-hub.se 参考文章(16)
Andrezza V. Belo, Mônica A. N. D. Ferreira, Adriana A. Bosco, Rosângela D. P. Machado, Silvia P. Andrade, Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation. ,vol. 25, pp. 91- 96 ,(2001) , 10.1023/A:1007114404953
Beth A. Pulaski, Suzanne Ostrand‐Rosenberg, Mouse 4T1 Breast Tumor Model Current Protocols in Immunology. ,vol. 39, ,(2000) , 10.1002/0471142735.IM2002S39
R. J. D'Amato, M. S. Loughnan, E. Flynn, J. Folkman, Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 4082- 4085 ,(1994) , 10.1073/PNAS.91.9.4082
Didier Bouscary, Laurence Legros, Micheline Tulliez, Stephanie Dubois, Beatrice Mahe, Odile Beyne-Rauzy, Marie C. Quarre, Dominique Vassilief, Bruno Varet, Achille Aouba, Martine Gardembas, Stephane Giraudier, Agnes Guerci, Philippe Rousselot, Fanny Gaillard, Anne Moreau, Marie C. Rousselet, Norbert Ifrah, Pierre Fenaux, Francois Dreyfus, , A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies. British Journal of Haematology. ,vol. 131, pp. 609- 618 ,(2005) , 10.1111/J.1365-2141.2005.05817.X
Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia-Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis, Hagop M. Kantarjian, Thalidomide therapy for myelofibrosis with myeloid metaplasia Cancer. ,vol. 106, pp. 1974- 1984 ,(2006) , 10.1002/CNCR.21827
Ai Kawamata, Daisuke Ito, Takeshi Odani, Tomohide Isobe, Masayasu Iwase, Masashi Hatori, Masao Nagumo, Thalidomide suppresses melanoma growth by activating natural killer cells in mice Oncology Reports. ,vol. 16, pp. 1231- 1236 ,(2006) , 10.3892/OR.16.6.1231
Yonal Ipek, Hindilerden Fehmi, Besisik-Kalayoglu Sevgi, Sargin Deniz, Thrombotic complications in multiple myeloma: a report of three cases and review of the literature Journal of Thrombosis and Thrombolysis. ,vol. 33, pp. 197- 201 ,(2012) , 10.1007/S11239-011-0636-Z
Anna Israyelyan, Felipe Sandoval, Abolghasem Baghian, Michael T. Kearney, Edward J. Shannon, Thalidomide delayed the ability of 4T1 cells to amass into tumors in Balb/c mice Immunopharmacology and Immunotoxicology. ,vol. 34, pp. 408- 412 ,(2012) , 10.3109/08923973.2011.611519
Suniket V. Fulzele, Abhijit Chatterjee, Madhu Sudhan Shaik, Tanise Jackson, Mandip Singh, Inhalation Delivery and Anti-tumor Activity of Celecoxib in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Model Pharmaceutical Research. ,vol. 23, pp. 2094- 2106 ,(2006) , 10.1007/S11095-006-9074-6
Yutaka Hattori, Yoshitaka Miyakawa, Kenji Yokoyama, Taketo Yamada, Wenlin Du, Masahiro Jinzaki, Hiroshi Shinmoto, Shinichiro Okamoto, Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis International Journal of Hematology. ,vol. 93, pp. 129- 131 ,(2011) , 10.1007/S12185-010-0733-3